In a study led by a multinational team of experts, researchers at National Jewish Health and their collaborators in Colorado, ...

In a groundbreaking study led by a multinational team of experts, researchers at National Jewish Health and their collaborators in Colorado, Illinois ...

In the U.S., pulmonary sarcoidosis affects around 200,000 patients. The cause is unknown, and no new treatments have been introduced in the past 70 years. Scientists now characterized a protein ...

SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) ("aTyr” or the "Company”), a clinical stage ...

As the effects of wildfires persist in several parts of the United States, McGowan highlighted a public health alert ...

Sarcoidosis is a rare systemic disease that afflicts an estimated 200,000 people in the U.S., more often people who are Black and more women than men, particularly when it causes chronic skin disease.

Announcement coincides with Foundation’s 25th anniversary and recent FMLA clarification supporting clinical trial ...

The US remains the largest pulmonary sarcoidosis market, both in terms of patient pool and market value. This dominance is attributed to higher diagnosis rates, advanced healthcare infrastructure ...

90% of patients living with sarcoidosis have lung involvement. Despite advances in research, sarcoidosis remains challenging to diagnose, with limited treatment options and no known cure.